Xueyi Pan
Overview
Explore the profile of Xueyi Pan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
57
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wang H, Peng J, Zeng W, Pan X
Clin Lab
. 2024 Feb;
70(2).
PMID: 38345991
Background: Hemophagocytic lymphohistiocytosis (HLH) is a severe inflammatory reaction syndrome caused by genetic or acquired immune dysregulation. The majority of adult HLH cases are caused by tumors, rheumatic immune disorders,...
2.
Li X, Sun X, Fang B, Leng Y, Sun F, Wang Y, et al.
Thromb J
. 2023 Oct;
21(1):105.
PMID: 37794471
Background: Individuals with multiple myeloma (MM) receiving immunomodulatory drugs (IMiDs) are at risk of developing venous thromboembolism (VTE), a serious complication. There is no established clinical model for predicting VTE...
3.
Zhou L, Guan Z, Chen C, Zhu Q, Qiu S, Liu Y, et al.
Front Cell Infect Microbiol
. 2023 Jan;
12:1072463.
PMID: 36699718
Introduction: () Microsporidia can cause opportunistic infections in immunocompromised patients and is also an emerging disease in these individuals. Its clinical manifestations are chronic diarrhea and severe wasting syndrome, these...
4.
Pi Y, Wang J, Zhou H, Ye X, Sun X, Liu L, et al.
J Cancer Res Clin Oncol
. 2022 Jul;
149(7):3033-3041.
PMID: 35852619
Purpose: Hemophagocytic lymphohistiocytosis (HLH), especially lymphoma-associated HLH (LA-HLH), is a refractory immune disorder with high mortality. There is still no consensus regarding the ideal treatment for LA-HLH. Methods: We performed...
5.
He Y, Gao Y, Ping L, He H, Huang C, Bai B, et al.
J Cancer Res Clin Oncol
. 2022 Jul;
149(5):2017-2027.
PMID: 35809114
Purpose: Anti-PD-1 antibody (anti-PD-1 mAb) showed favorable outcomes in some patients with relapsed/refractory (r/r) extranodal NK/T-cell lymphoma (ENKTL). However, the role of anti-PD-1 antibody in NK/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis (NK/T-LAHS)...
6.
Zhu Q, Li H, Zheng S, Wang B, Li M, Zeng W, et al.
Front Immunol
. 2022 Apr;
13:856039.
PMID: 35432366
To investigate the Th1/Th2 cytokine profile in patients with lymphoma during the myelosuppression stage of infection. 52 patients with gram-negative bacterial infection (G- group), 49 patients with gram-positive bacterial infection...
7.
Zhu Q, Yang S, Zeng W, Li M, Guan Z, Zhou L, et al.
Front Oncol
. 2021 Sep;
11:701539.
PMID: 34490101
This real-world, observational study aimed to assess and compare the clinical efficacy and safety of eltrombopag with recombinant human thrombopoietin (rhTPO) in the treatment of chemotherapy induced thrombocytopenia (CIT) in...
8.
Tian Y, Gao Y, Pan X, Liu Q, Wang J, Jin M, et al.
Nanotechnology
. 2021 Mar;
32(27).
PMID: 33765668
Low-viscosity UV-curable resins are widely used in industry as they allow for UV curing materials with reduced amounts of reactive diluents to adjust the viscosity. But their mechanical properties and...
9.
Xu L, Wang X, Pan X, Wang X, Wang Q, Wu B, et al.
BMC Cancer
. 2020 Aug;
20(1):737.
PMID: 32770980
Background: Disparities in multiple myeloma (MM) prognosis based on sociodemographic factors may exist. We investigated whether education level at diagnosis influenced Chinese MM patient outcomes. Methods: We performed a multicenter...
10.
Zhou L, Liu Y, Wen Z, Yang S, Li M, Zhu Q, et al.
J Cancer Res Clin Oncol
. 2020 Jul;
146(11):3063-3074.
PMID: 32617699
Purpose: Case reports suggest that ruxolitinib-containing treatment could increase the clinical response rate of patients with hemophagocytic syndrome (HPS). This study aimed to explore the effect of ruxolitinib-containing treatment for...